Stocktwits on MSN20h
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps
Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...
Business Insider1d
Promising Potential of Aclaris Therapeutics’ BSI-045B and Pipeline Elevates Buy Rating
Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept ...
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...
Pharmabiz7h
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...
Aclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy Rating
BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...